Illumina: Q3 Earnings Snapshot
Illumina Inc. (ILMN) reported Q3 net income of $220 million, or $1.43 per share, beating analyst estimates of $1.36 per share. Revenue was $1.13 billion, slightly below expectations of $1.14 billion. The company expects full-year earnings of $5.40-$5.45 per share and revenue of $4.64-$4.66 billion.
How this was made
The 30-second read
Why it matters
The combination of an adjusted EPS beat, a revenue miss, and explicit full-year guidance creates a clear setup for traders to reassess valuation and forward estimates immediately after the print.
Market read
This is a direct earnings-and-guidance disclosure with quantified beat/miss and full-year ranges, which typically drives same-day positioning and estimate revisions.
What to watch
Traders may focus on the gap between EPS and revenue drivers (mix, costs, or one-time items) rather than the headline beat, which the snapshot only partially characterizes.
Background
The piece is an AP-generated earnings snapshot for Illumina’s third quarter, referencing analyst expectations from Zacks.
Ticker impact
Illumina reported Q3 net income of $220M and EPS $1.44 (adjusted) versus $1.36 expected, plus full-year EPS guidance of $5.40 to $5.45.
Likely modest upside bias from the EPS beat, partially offset by the revenue miss and any concerns about forward growth implied by guidance.
The article discloses both the earnings beat and the revenue shortfall, along with explicit full-year EPS and revenue ranges, which are the key inputs traders use for immediate sentiment and positioning.
Market effects
Provides a read-through for genetic testing tools demand and pricing power, which can influence sentiment across genomics-instrument peers.
Primarily US-listed large-cap biotech/genomics sentiment; limited direct regional spillover beyond healthcare tech.
Genomics tooling results can affect global investor appetite for life-science instrumentation, though the article is US-focused.
Counterpoint
The revenue miss could dominate if investors view it as a leading indicator for future procedure volumes or instrument utilization, despite the EPS beat.
Key entities
- companyIllumina Inc.
Genetic testing tools company reporting Q3 results and full-year guidance.
- sourceZacks Investment Research
Cited as the provider of analyst consensus estimates used for the beat/miss comparison.
